# S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

> **NCT05312372** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Institut de Recherches Internationales Servier**

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Combination (S095033 + paclitaxel)

## Key facts

- **NCT ID:** NCT05312372
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Strategic development reasons
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312372, "S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05312372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*